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Understanding the regulation of red blood cell production has been greatly enhanced by the
cloning and expression of the gene for human erythropoietin (Epo) and its receptor. The
availability of recombinant human erythropoietin (rhEpo) for administration to patients has
ushered in a newera in molecular medicine. Intravenous orsubcutaneous administration ofrhEpo
can reliably cure the anemia of chronic renal failure and may be effective in the treatment of
anemias secondary to chronic inflammation, malignancy, and marrow suppression from chemo-
therapy. In addition, rhEpo therapy will probably play a prominent role in transfusion medicine,
both in preparing patients for auto-transfusions as well as in minimizing red cell transfusion
requirements in the post-operative period.
One of the most dramatic successes in the application of modern molecular biology
to medicine has been the cloning of the erythropoietin (Epo) gene [1,2] and the
high-level expression ofrecombinant human Epo (rhEpo), enabling its administration
to patients. In this brief review, I will first discuss erythropoiesis, in vitro and in vivo,
and its regulation by Epo. This background information is highly relevant to the
development of rhEpo for effective treatment of various anemias as well as to other
aspects oftransfusion medicine.
ERYTHROPOIESIS
Erythroid progenitor cells are direct descendants of trilineage hematopoietic stem
cells, as shown in Fig. 1. Early erythroid differentiation is stimulated by at least two
hematopoieticgrowthfactors: interleukin 3 (IL-3) andgranulocyte-macrophage colony-
stimulating factor (GM-CSF). These lymphokines appear to be liberated by both
macrophages and T lymphocytes, probably triggered by cell-cell interactions. Two
types oferythroid progenitor cells have been identified by culture in semi-solid media:
BFUe (burst-forming unit, erythroid) and CFUe (colony-forming unit, erythroid).
After eight to ten days in culture, a single BFUe proliferates into a burst colony,
containing up to 2,000 nucleated erythroid cells in discrete subcolonies. The BFUe is
moderately sensitive to erythropoietin but also requires other hematopoietic growth
factors, as mentioned above. BFUe differentiate into CFUe. The CFUe can be readily
identified after two to three days in culture. A single CFUe proliferates into a small
colony, containing 8 to 64 nucleated erythroid cells. The CFUC is highly sensitive to
erythropoietin. Thus theCFUe, under the influenceofEpo, differentiates intoerythroid
precursors, readily identified by the accumulation ofhemoglobin in thecytoplasm.
The maturation from the earliest recognizable erythroid precursor to the fully
developed red cell normally spans four tosixdaysand involves four to fivecell divisions.
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FIG. 1. Differentiation and maturation of erythroid cells. Erythroid progenitor cells are derived from
pluripotent stem cells shown on left. Under the influence of Epo, committed erytbroid progenitor cells
progress through the BFU, and CFU, stages into proerythroblasts, the earliest recognizable red cell
precursor in the bone marrow. During further maturation, globin mRNA accumulates, directing the cell to
produce hemoglobin (from Bunn HF: Pathophysiology of the anemias. In Harrison's Principles of Internal
Medicine, 12th edition. Edited by E Braunwald et al. New York, McGraw-Hill, 1990).
The nucleus is shed during the passage from the hematopoietic compartment of the
marrow into the vascular sinus. The neonatal red cell (the reticulocyte) becomes much
more deformable following the loss ofits nucleus.
ERYTHROPOIETIN
This circulating polypeptide hormone is the primary regulator of erythropoiesis in
man and other mammals. As shown in Fig. 2, this regulation is based on an elegant
"negative feedback" servomechanism, whereby hypoxia is sensed in the kidney,
resulting in increased production ofEpo by the kidney. Because ofan elevated level of
Epo in the plasma, marrow erythroid precursor cells (primarily CFUC) are allowed to
proliferate anddifferentiate, leading toan increase in the red cell mass. If, as expected,
this expansion of red cells corrects the hypoxia, Epo production in the kidney will be
suppressed.
The human erythropoietin gene encodes a protein of 193 amino acids. Following
cleavage of a 27 amino acid N terminal "leader" sequence, the mature protein has a
calculated molecular weight of 18,490. Human Epo circulating in plasma lacks its C
terminal amino acid, arginine. This residue is probably cleaved by an intracellular
carboxypeptidase prior to export from the kidney; it is not known whether this
modification has any functional significance. Post-translational glycosylation is clearly
required for in vivo function. Human Epo contains 39 percent carbohydrate, giving it a
molecular weight of 30,400. Complex N-linked glycosylation takes place on three
asparagine residues. Human and monkey Epo have one 0-linked glycosylation site at
residue Serine 126. In addition, both human and monkey Epos contain two disulfide
bonds. Both appear to be essential for the function ofthe molecule. One of the disulfide
bonds tethers the N terminal and C terminal ends of the molecule together. The
three-dimensional structure of Epo has not yet been determined; however, computer-
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FIG. 2. Regulation of Epo production in the kidney. A hypoxic signal triggers
increased production of Epo in the kidney. The increased level of Epo in the plasma
stimulates committed erythroid progenitors in the bone marrow to increase red cell
production.
based modeling suggests that the molecule probably folds into a globular structure,
having two anti-parallel pairs ofhelical bundles.
The cloning of the Epo gene has permitted large-scale production of human Epo.
The carbohydrate structure of the recombinant molecule does not differ significantly
from that of native Epo. Moreover, rhEpo has the same disulfide bond structure as
native Epo. Indeed, no significant structural differences between the two molecules
have been reported. After intravenous infusion, both the native and the recombinant
molecules have a half-life in theplasma ofabout five hours.
The mechanism of action of Epo is not well understood. The hormone binds to a
specific receptor, which is expressed only on erythroid precursor cells; this unique 507
residue membrane protein has recently been cloned and expressed [3]. The entire
molecule is rich in cysteine residues. The Epo receptor has a single trans-membrane
domain. Its cytoplasmic domain is rich in proline residues and lacks any homology to
tyrosine kinases; its mRNA is detected only in erythroid precursor cells. The Epo
receptor is a member of a recently recognized family ofgrowth factor receptors; it has
sequence homology with receptors for granulocyte-macrophage colony-stimulating
factor, interleukin 3, interleukin 4, interleukin 6, and with the ni subunit of the
interleukin 2 receptor. The Epo receptor appears to be oriented as a homodimer on the
surface oferythroid cells. Only the subset of receptors with high affinity for Epo has
biologic activity.
Very little is known about the molecular events following the binding of Epo to its
receptor that lead to proliferation and differentiation of erythroid cells. In addition to
stimulating division ofCFUC, thereby increasing production oferythroblasts, erythro-
poietin also hastens the rate at which erythroid cell divisions occur and lowers the
barrier between marrow and blood that normally retains young reticulocytes in the
marrow compartment [4]. The binding of Epo to its receptor results in both the
proliferation and the terminal maturation of erythroid cells, with induction ofbiosyn-
thesis oferythroid-specific proteins such as hemoglobin and certain red cell membrane
proteins (Fig. 1). There is growing evidence that the Epo-responsive precursor cell is
already destined to differentiate into erythroid cells and that Epo salvages these
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dividing cells from programmed death, thereby allowing expansion ofred cell produc-
tion [5].
EPO PRODUCTION
In the fetus, the liver is the primary source of Epo. After birth, the kidney is the
major site of production [6]; the kidney is a logical site because it would sense the
redistribution ofblood flow in mild anemia. The precise localization ofEpo production
in the kidney is controversial; the best evidence to date favors a subset of peritubular
interstitial (endothelial) cells in the boundary between the inner cortex and the outer
medulla [7,8]. The liver is normally a less important source ofEpo, but it can be called
upon in patients with impaired or absent renal function. The level ofEpo mRNA in the
kidney increases by at least twentyfold when an animal issubjected to acutehypoxia or
treated with cobalt chloride, an agent known to induce erythrocytosis in experimental
animals in association with increased levels ofplasma Epo.
Epo is produced in a regulated fashion in a human hepatoma (liver carcinoma) cell
line (Hep3B) [9]. In these cells, both hypoxia and cobalt chloride trigger a 50- to
100-fold increase in Epo mRNA. Recent studies in Hep3B cells suggest that the
oxygen sensor for erythropoietin regulation is a heme protein. A likely mechanism
whereby cobalt induces Epo production is by substituting for iron in the heme group of
the sensor protein, thereby mimicking the deoxy state [9]. When Hep3B cells are
challenged with either hypoxia or cobalt, there is both increased transcription of the
Epo gene and enhanced stability ofthe Epo mRNA.
THERAPY OF ANEMIA OF UREMIA WITH rhEpo
In patients with uremia the severity of anemia is roughly related to the degree of
renal failure. Although some patients tolerate their anemia fairly well, it is often a
major cause of limitation in activity and even of disability. Plasma Epo is lower in
uremic patients compared to levels in patients with other types ofanemia ofcompara-
ble severity.
A number of clinical trials have shown that the intravenous administration of
recombinant human Epo three times weekly will enable most patients to achieve and
maintain a normal red cell mass [10-12]. As shown in Fig. 3, initial treatment is
associated with reticulocytosis and an increase in red cell utilization ofiron, reflecting
effective erythropoiesis [10]. This treatment is expected to relieve the secondary iron
overload that is commonly encountered in renal dialysis patients, particularly if they
have been transfused. Too rapid restoration of red cell mass can cause significant
hypertension; however, no other significant adverse effects have been noted either in
uremic patients or in those with other types of anemias. A theoretical pitfall is the
development of antibodies to rhEpo owing to possible subtle differences in carbohy-
drate structure .between the native and recombinant molecules. Among over 1,000
patients who have been treated with rhEpo thus far, however, none have become
refractory to therapy owing to the development of antibodies. The treatment of
hemodialysis patients with rhEpo has been extremely gratifying. A large proportion
have reported a striking improvement intheirperformancestatus andoverallqualityof
life [13]. Uremic patients who are not yet dependent on dialysis have also benefited
from rhEpo therapy without any detectable effect in the rate ofdeterioration of renal
function [14]. Recently, the subcutaneous administration of rhEpo has been shown to
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FIG. 3. Response of a patient with renal
failure on hemodialysis to the administration
of recombinant human Epo (rHuEpo). The
same time scale (weeks) applies to both the
upperandlowerpanels. Priorto Epotherapy,
the patient required frequent blood transfu-
sions (vertical arrows). The top panel shows
thehematocrit, whilethe bottompanel shows
the concomitant percentage of reticulocytes
over a 26-week period. The box insert shows
changes inserumiron (Fe), totaliron binding
capacity (TIBC), percentage of iron satura-
tion (% Sat.), and serum ferritin. Note that
Epo therapy resulted in reticulocytosis and
subsequent increase in hematocrit, with ces-
sation ofrequirement for blood transfusions.
The increase in red cell mass was associated
witha significantdepletionofbodyironstores
(from [9]).
be both safe and effective. The peak plasma levels of Epo are much lower than those
following intravenous therapy, but the delivery ofthe rhEpo is more sustained.
OTHER APPLICATIONS OF rhEpo
Unlike the anemia of uremia, other types of anemia are associated with an
exponential increase in the level ofplasma Epo in proportion to the decrease in red cell
mass [15]. Patients with high plasma Epo levels might not be expected to respond to
rhEpo therapy. Nevertheless, recent clinical trials have demonstrated a significant
improvement in hematocrit in patients with the anemia of chronic inflammation
(particularly patients with rheumatoid arthritis) [16] and with the anemia of malig-
nancy. In addition, rhEpo will probably prove to be useful in hastening the recovery of
erythropoiesis following marrowtransplantation orchemotherapy. In particular, rhEpo
has proven to be effective in AIDS patients with myelosuppression secondary to
treatment with azidothymidine and in patients with testicular cancer who have been
treated with cis-platinum. Administration of rhEpo has been proposed as a means of
increasing the level of fetal hemoglobin in patients with sickle-cell anemia, thereby
impairing the polymerization of Hb S. Unfortunately, we have not observed any
significant increase in Hb F in fiveSS patients who have been treated with high doses of
rhEpo.
Ofparticular relevance to transfusion medicine is use ofrhEpo in the preparation of
patients for elective surgery, enhancing the numberofunits that can safely be removed
and preserved for autologous transfusion in the peri-operative and post-operative
periods. Well-designed studies both in primates [17] and in man [18] indicate that this
strategy is safe and effective. Moreover the administration of rhEpo may be useful in
decreasing the amount of red cell transfusions required in the post-operative period.
Finally, rhEpo may be useful in enhancing the amount of blood that can be removed
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from donors. It is likely that rhEpo treatment would enable a reduction in the minimal
interval (currently eight weeks) between repeat phlebotomies. This treatment might
facilitate a recipient's receiving multiple transfusions ofblood from the samedonorand
therefore a reduction in the incidence oftransfusion-transmitted diseases.
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